Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort
Objective This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve diseases (HVDs).Methods This prospective study included consecutive patients with SLE who visited Peking Union Medical College Hospital between April 1999 and December 2024. Ech...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-06-01
|
| Series: | Lupus Science and Medicine |
| Online Access: | https://lupus.bmj.com/content/12/1/e001674.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849424626567872512 |
|---|---|
| author | Wei Bai Shangzhu Zhang Xiaofeng Zeng Hui Jiang Jiuliang Zhao Mengtao Li Yan Zhao Junyan Qian Ziqian Wang Can Huang Yuan Zhao Xiaoxiao Guo Liying Peng Siyun Chen Yangzhong Zhou Chuhan Wang |
| author_facet | Wei Bai Shangzhu Zhang Xiaofeng Zeng Hui Jiang Jiuliang Zhao Mengtao Li Yan Zhao Junyan Qian Ziqian Wang Can Huang Yuan Zhao Xiaoxiao Guo Liying Peng Siyun Chen Yangzhong Zhou Chuhan Wang |
| author_sort | Wei Bai |
| collection | DOAJ |
| description | Objective This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve diseases (HVDs).Methods This prospective study included consecutive patients with SLE who visited Peking Union Medical College Hospital between April 1999 and December 2024. Echocardiography was performed based on clinical indications. Clinical characteristics, aPL profiles and echocardiographic findings were collected. Logistic regression was used to evaluate associations between aPLs and HVD.Results Among 508 patients with SLE, 27.4% had HVD. The most frequently affected valves were aortic (17.3%) and mitral (11.2%) valves, with thickening (19.5%) and regurgitation (15.9%) as the leading lesion types. aPLs positive patients with SLE had higher rates of HVD (35.1% vs 24.0%, p=0.010), including valve thickening (25.3% vs 16.9%, p=0.028), regurgitation (24.7% vs 12.1%, p<0.001), vegetations (9.1% vs 0.8%, p<0.001) and stenosis (1.9% vs 0.0%, p=0.008). Anticardiolipin-IgG was associated with HVD (OR=2.484, p=0.003), mitral lesions (OR=4.156, p<0.001), valve thickening (OR=2.255, p=0.011) and regurgitation (OR=2.121, p=0.014). Anti-β2 glycoprotein I-IgG showed similar associations and was also linked to valve stenosis (OR=11.209, p=0.022). Lupus anticoagulant (LA) was associated with valve vegetations (OR=8.659, p<0.001) and interventional/surgical indications (OR=6.868, p=0.005).Conclusion aPLs, especially IgG isotype and LA, are independently associated with diverse HVD in SLE. Echocardiographic monitoring is warranted in aPL-positive patients. |
| format | Article |
| id | doaj-art-af0de15c78fb45efac52c4dbf0fb527a |
| institution | Kabale University |
| issn | 2053-8790 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Lupus Science and Medicine |
| spelling | doaj-art-af0de15c78fb45efac52c4dbf0fb527a2025-08-20T03:30:04ZengBMJ Publishing GroupLupus Science and Medicine2053-87902025-06-0112110.1136/lupus-2025-001674Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohortWei Bai0Shangzhu Zhang1Xiaofeng Zeng2Hui Jiang3Jiuliang Zhao4Mengtao Li5Yan Zhao6Junyan Qian7Ziqian Wang8Can Huang9Yuan Zhao10Xiaoxiao Guo11Liying Peng12Siyun Chen13Yangzhong Zhou14Chuhan Wang15State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaDepartment of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaObjective This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve diseases (HVDs).Methods This prospective study included consecutive patients with SLE who visited Peking Union Medical College Hospital between April 1999 and December 2024. Echocardiography was performed based on clinical indications. Clinical characteristics, aPL profiles and echocardiographic findings were collected. Logistic regression was used to evaluate associations between aPLs and HVD.Results Among 508 patients with SLE, 27.4% had HVD. The most frequently affected valves were aortic (17.3%) and mitral (11.2%) valves, with thickening (19.5%) and regurgitation (15.9%) as the leading lesion types. aPLs positive patients with SLE had higher rates of HVD (35.1% vs 24.0%, p=0.010), including valve thickening (25.3% vs 16.9%, p=0.028), regurgitation (24.7% vs 12.1%, p<0.001), vegetations (9.1% vs 0.8%, p<0.001) and stenosis (1.9% vs 0.0%, p=0.008). Anticardiolipin-IgG was associated with HVD (OR=2.484, p=0.003), mitral lesions (OR=4.156, p<0.001), valve thickening (OR=2.255, p=0.011) and regurgitation (OR=2.121, p=0.014). Anti-β2 glycoprotein I-IgG showed similar associations and was also linked to valve stenosis (OR=11.209, p=0.022). Lupus anticoagulant (LA) was associated with valve vegetations (OR=8.659, p<0.001) and interventional/surgical indications (OR=6.868, p=0.005).Conclusion aPLs, especially IgG isotype and LA, are independently associated with diverse HVD in SLE. Echocardiographic monitoring is warranted in aPL-positive patients.https://lupus.bmj.com/content/12/1/e001674.full |
| spellingShingle | Wei Bai Shangzhu Zhang Xiaofeng Zeng Hui Jiang Jiuliang Zhao Mengtao Li Yan Zhao Junyan Qian Ziqian Wang Can Huang Yuan Zhao Xiaoxiao Guo Liying Peng Siyun Chen Yangzhong Zhou Chuhan Wang Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort Lupus Science and Medicine |
| title | Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort |
| title_full | Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort |
| title_fullStr | Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort |
| title_full_unstemmed | Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort |
| title_short | Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort |
| title_sort | impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus based on cstar cohort |
| url | https://lupus.bmj.com/content/12/1/e001674.full |
| work_keys_str_mv | AT weibai impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort AT shangzhuzhang impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort AT xiaofengzeng impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort AT huijiang impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort AT jiuliangzhao impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort AT mengtaoli impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort AT yanzhao impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort AT junyanqian impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort AT ziqianwang impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort AT canhuang impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort AT yuanzhao impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort AT xiaoxiaoguo impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort AT liyingpeng impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort AT siyunchen impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort AT yangzhongzhou impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort AT chuhanwang impactofantiphospholipidantibodiesonheartvalveinvolvementsinsystemiclupuserythematosusbasedoncstarcohort |